References

1. Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS. 2000;14(1):6974.

2. Marder K, Stern Y, Malouf R, Tang MX, Bell K, Dooneief G, el-Sadr W, Goldstein S, Gorman J, Richards M, et al. Neurologic and neuropsychological manifestations of human immunodeficiency virus infection in intravenous drug users without acquired immunodeficiency syndrome. Relationship to head injury. Arch Neurol. 1992;49(11): 11691175.

3. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587): 979980.

4. Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. Western J Med. 1998;168(2): 9397.

5. Egan VG, Crawford JR, Brettle RP, Goodwin GM. The Edinburgh cohort of HIV-positive drug users: Current intellectual function is impaired, but not due to early AIDS dementia complex. AIDS. 1990;4(7):651656.

6. Concha M, Graham NM, Munoz A, Vlahov D, Royal W 3d, Updike M, NanceSproson T, Selnes OA, McArthur JC. Effect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity. Am J Epidemiology. 1992;136(11):13381348.

7. Chiesi A, Seeber AC, Dally LG, Floridia M, Rezza G, Vella S. AIDS dementia complex in the Italian National AIDS Registry: Temporal trends (198793) and differential incidence according to mode of transmission of HIV-1 infection. J Neurol Sci. 1996;144(12):107113.

8. Jougla E, Pequignot F, Carbon C, Pavillon G, Mireille EB, Bourdais JP, Bourdais O, Hatton F. AIDS-related conditions: Study of a representative sample of 1203 patients deceased in 1992 in France. Int J Epidemiol. 1996; 25(1):190197.

9. Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, Schwander S, Goebel FD, Glauser M, Antunes F, et al. Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquired Immune Deficiency Syndromes and Human Retrovirology. 1996;11(1):3944.

10. Wang F, So Y, Vittinghoff E, Malani H, Reingold A, Lewis E, Janssen R. Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis. J Acquired Immune Deficiency Syndromes and Human Retrovirology. 1995;8(1):7582.

11. Martinez AJ, Sell M, Mitrovics T, StoltenburgDidinger G, IglesiasRozas JR, GiraldoVelasquez MA, Gosztonyi G, Schneider V, CervosNavarro J. The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Pathology, Research and Practice. 1995;191(5):427443.

12. Davies J, Everall IP, Weich S, McLaughlin J, Scaravilli F, Lantos PL. HIV-associated brain pathology in the United Kingdom: An epidemiological study. AIDS. 1997;11(9):11451150.

13. Baldwin GC, Roth MD, Tashkin DP. J Neuroimmunol. 1998;83(12):133138

14. Nair MP, Chadha KC, Hewitt RG, Mahajan S, Sweet A, Schwartz SA. Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol. 2000;7(1):96100.

15. Goodkin K, Shapshak P, Metschf, LR, McCoy CB., Crandall KA, Kumar M, Fujimura RK., McCoy V, Zhang, BT Reyblat S, Xinn K-Q, Kumar AM. Cocaine abuse and HIV-1 infection: Epidemiology and neuropathogenesis.

J Neuroimmunol. 1998;83(12):88101.

16. Hoff AL, Riordan H, Morris L, Cestaro V, Wieneke M, Alpert R, Wang GJ, Volkow N. Effects of crack cocaine on neurocognitive function. Psych Res. 1996;60(23):167176.

17. Bauer LO. Psychomotor and electroencephalographic sequelae of cocaine dependence. Nida Research Monograph. 1996;163:6693.

18. Bartzokis G, Beckson M, Hance DB, Lu PH, Foster JA, Mintz J, Ling W, Bridge P. Magnetic resonance imaging evidence of "silent" cerebrovascular toxicity in cocaine dependence. Biological Psychiatry. 1999;45(9):12031211.

19. Chang L, Mehringer CM, Ernst T, Melchor R, Myers H, Forney D, Satz P, Neurochemical alterations in asymptomatic abstinent cocaine users: A proton magnetic resonance spectroscopy study. Biol Psychiatry. 1997;42(12): 11051114.

20. Berger JR, Nath A. HIV dementia and the basal ganglia. Intervirol. 1997;40(23):122131.

21. Holman BL, Garada B, Johnson KA, Mendelson J, Hallgring E, Teoh SK, Worth J, Navia B. A comparison of brain perfusion SPECT in cocaine abuse and AIDS dementia complex. J Nucl Med. 1992;3(7):13121315.

22. Zhang L, Looney D, Taub D, Chang SL, Way D, Witte MH, Graves MC, Fiala M. Cocaine opens the bloodbrain barrier to HIV-1 invasion. J Neurovirol. 1998;4(6):619626.

23. Gan X, Zhang L, Berger O, Stins MF, Way D, Taub DD, Chang SL, Kim KS, House SD, Weinand M, et al. Cocaine enhances brain endothelial adhesion molecules and leukocyte migration. Clin Immunol. 1999;91(1):6876.

24. Fiala M, Gan XH, Zhang L, House SD, Newton T, Graves MC, Shapshak P, Stins M, Kim KS, Witte M, et al. Cocaine enhances monocyte migration across the bloodbrain barrier. Cocaines connection to AIDS dementia and vasculitis? Advances in Experimental Medicine and Biology. 1998,437:199205.

25. Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. Western J Med. 1998;168(2):9397.

26. House RV, Thomas PT, Bhargava HN. Comparison of immune functional parameters following in vitro exposure to natural and synthetic amphetamines. Immunopharmacology and Immunotoxicology. 1994;16(1):121.

27. Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology. 2000;54(6):13441349.

28. Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, Ravert HT, Musachio J, McCann UD, Ricaurte GA. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations.

J Neurosci. 1998;18(1):419427.

29. Gisslen M, Larsson M, Norkrans G, Fuchs D, Wachter H, Hagberg L. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. Aids Research and Human Retroviruses. 1994;10(8):947951.

30. Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection.

J Neuroimmunol. 1998;83(12):418.

31. Govitrapong P, Suttitum T, Kotchabhakdi N, Uneklabh T. Alterations of immune functions in heroin addicts and heroin withdrawal subjects. J Pharmacology and Experimental Therapeutics. 1998;286(2): 883889.

32. Freier DO, Fuchs BA. A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity. J Pharmacology and Experimental Therapeutics. 1994;270(3): 11271133.

33. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol. 1998;83(12):7787.

34. Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology. 2000;23(2):113126.

35. Ploechl W, Eder H, Kasper S. Cerebral CT findings in male opioid-dependent patients: stereological, planimetric and linear measurements. Psych Res. 1998; 83(3):139147.

36. Oehmichen M, Meissner C, Reiter A, Birkholz M. Neuropathology in non-human immunodeficiency virus-infected drug addicts: hypoxic brain damage after chronic intravenous drug abuse. Acta Neuropathologica. 1996;91(6):642646.

37. Kriegstein AR, Shungu DC, Millar WS, Armitage BA, Brust JC, Chillrud S, Goldman J, Lynch T. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation (chasing the dragon). Neurology. 1999;53(8): 17651773.

38. Bell JE, Brettle RP, Chiswick A, Simmonds P.HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain. 1998;121(Pt 11):20432052.

39. Tomlinson GS, Simmonds P, Busuttil A, Chiswick A, Bell JE. Upregulation of microglia in drug users with and without pre-symptomatic HIV infection. Neuropathology and Applied Neurobiology. 1999;25(5):369379.

40. Shepard EJ, Brettle RP, Liberski PP, Aguzzi A, Ironside JW, Simmonds P, Bell JE. Spinal cord pathology and viral burden in homosexuals and drug users with AIDS. Neuropathology and Applied Neurobiology. 1999;25(1):210.

41. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psych. 1997; 154(6):805811.

42. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biological Psychiatry. 1998;43(11): 811816.

43. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Segura J, de la Torre R. Immunomodulating

properties of MDMA alone and in combination with alcohol: A pilot study. Life Sciences. 1999;65(26):PL309316

44. Ricaurte GA, Yuan J, McCann UD. (+/)3,4Methylenedioxymethamphetamine (Ecstasy)-induced serotonin neurotoxicity: Studies in animals. Neuropsychobiology. 2000;42(1):510.

45. Simantov R, Tauber M. The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. FASEB J. 1997;11(2):141146.

46. Wareing M, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA (Ecstasy). British J Psychol. 2000;91(Pt 2):181188.

47. Parrott AC. Human research on MDMA(3,4methylenedioxymethamphetamine) neurotoxicity: Cognitive and behavioural indices of change. Neuropsychobiology. 2000;42(1):1724.

48. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA (Ecstasy) on brain serotonin neurons in human beings

[see comments]. Lancet. 1998;352(9138): 14331437.

49. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Internal Med. 1999;159(18):22212224.

close window